Venetoclax combined with multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction therapy for patients with de novo acute leukaemia of ambiguous lineage
Abstract Acute leukaemia of ambiguous lineage (ALAL) is a rare and heterogeneous leukaemia with unsatisfactory outcomes from conventional chemotherapy. Venetoclax (VEN) has shown potential efficacy in ALAL. Our pilot study demonstrated that VEN combined with multi-frequency decitabine (DEC) was safe and effective in elderly acute myeloid leukaemia (AML) patients. We therefore designed VDVD regimen (VEN, multi-frequency DEC, vincristine, dexamethasone) as induction therapy for de novo ALAL. VDVD comprised VEN (100 mg d1, 200 mg d2, 400 mg d3-11), DEC (20 mg/m² every 8 hours d4-6), vincristine (2 mg/d d1,8), and dexamethasone (10 mg/m² d1-4,8–11). Dasatinib was added for BCR::ABL1-positive patients. Hematopoietic stem cell transplantation (HSCT) was recommended upon achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi). The primary endpoint was overall response rate (ORR); secondary endpoints included overall survival (OS), event-free survival (EFS) and disease-free survival (DFS). This multicenter retrospective study included 19 patients with de novo ALAL (median age 58 years, range 15–71) from 8 hospitals in China, all of whom were treated with the VDVD regimen.After one induction cycle, ORR(CR + morphologic leukaemia-free state, MLFS + partial remission, PR) was 94.73% (18/19), with CR rate of 84.21% (16/19). No induction deaths occurred. At median follow-up of 11 months (range 2–36), 3 (15.79%) patients underwent HSCT. Median OS was 11 months (range 2–36), median EFS and DFS were both 9.5 months (range 1–31). In conclusion, the VDVD regimen demonstrates promising efficacy and a manageable safety profile as induction therapy for de novo ALAL.
Authors
- Guanchen Bai
- 白炎亮
- 索晓慧
- Junshi Zhang (ORCID: https://orcid.org/0000-0001-7335-3104)
- Jie Liu (ORCID: https://orcid.org/0009-0006-5054-4550)
- Ling Li
- Ruixia Sun
- Xinxiao Lu
- Yafang Chen
- Fang Zheng
- Xingli Zhao
- Kaiqi Liu
- Yingchang Mi
Institutions
- Handan College (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Nankai University (CN)
- China National Pharmaceutical Group Corporation (China) (CN)
- Tianjin Nankai Hospital (CN)
- Inner Mongolia People's Hospital (CN)
- Henan Provincial People's Hospital (CN)
- The First People's Hospital of Guiyang (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Taian City Central Hospital (CN)
- State Key Laboratory of Experimental Hematology (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1038/s41598-026-79095-9
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00